Product Pipeline

Innovative, first-in-class product candidates for prevention and treatment.

Overview

Our two lead candidates with a human microbiome focus are: ribaxamase to prevent C. difficile infection (CDI) and antibiotic-associated diarrhea (AAD) and SYN-010 to treat irritable bowel syndrome with constipation (IBS-C).

Our research candidates include monoclonal antibody therapies for the prevention and treatment of Pertussis and novel biotherapeutics for the treatment of patients with phenylketonuria (PKU).

Microbiome-Focused Pipeline

Candidate & Indication Development Stage
Preclinical Phase 1 Phase 2 Phase 3 Market
SYN-004 (ribaxamase) Prevention of CDI and AAD
Preclinical Phase complete
Phase 1 Phase complete
Phase 2 Phase in progress
Phase 3 Phase not started
Market Phase not started
SYN-010 Treatment of IBS-C
Preclinical Phase complete
Phase 1 Phase complete
Phase 2 Phase in progress
Phase 3 Phase not started
Market Phase not started

SYN-004 (ribaxamase)

Designed to be co-administered with IV beta-lactam antibiotics, ribaxamase is an oral enzyme tablet that allows the IV antibiotic to treat the infection, while protecting the gut microbiome and preventing CDI and AAD.

View SYN-004 (ribaxamase)

SYN-010

SYN-010 is a proprietary, modified-release formulation of lovastatin lactone that is designed to reduce methane production in the intestine, curbing IBS-C.

View SYN-010